Medibio (ASX:MEB) has announced that a DSM-V 1 diagnosis will be included as a primary comparator for the purposes of assessing the efficacy of its depression algorithms, MEB-001. …
FDA confirms a diagnostic method for Medibio’s final depression validation trial
May 19, 2022 Australian Biotech
Latest Video
New Stories
-
Australian researchers identify new drug target for inflammatory lung disease
July 5, 2022 - - Latest News -
Is this what health technology assessment has become in Australia?
July 5, 2022 - - Latest News -
TGA authorises government campaign promoting COVID-19 treatments
July 4, 2022 - -
Pre-Budget spending rules not quite that strict after all
July 4, 2022 - - Latest News -
The health system review that is not even being led by health
July 4, 2022 - - Latest News -
Few should expect 'ministerial discretion' and few should actually apply
July 4, 2022 - - Latest News -
Novartis considers spin-out of Sandoz off-patent division
July 4, 2022 - - Latest News